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ORIGINAL ARTICLES
Initiating antiretroviral therapy (ART) at a CD4 cell count of 
≤350 cells/µl has better outcomes than postponing treatment until 
more immune system damage has occurred,1 an opinion endorsed 
in expert guidelines from the World Health Organization, US 
Public Health and other academic institutions.2,3 Some experts 
have motivated for even earlier ART initiation (CD4 count ≤500 
cells/µl) to improve patient outcomes and to lower viral loads in 
communities to decrease HIV transmission events, a strategy known 
as ‘treatment as prevention’.4 Better ART drugs and a rapid drug-
development pipeline favour earlier introduction of treatment. Until 
recently, the South African ART guidelines diverged from world 
opinion in delaying initiation in HIV-positive adults who are not 
pregnant or tuberculosis (TB) co-infected until a CD4 count of 200 
cells/µl was  reached.5 The South African Government (SAG) has 
recently announced that it will raise the CD4 threshold to 350 cells/
µl for all HIV-positive clients accessing state facilities for sponsored 
ART. This should be applauded and will provide an opportunity to 
lower transmission rates at community level, especially in groups 
who have the highest risk for HIV transmission, including men 
who have sex with men (MSM), commercial sex workers (CSWs), 
substance abusers, particularly intravenous drug users (IDUs), and 
serodiscordant couples.
Modelling studies demonstrate that targeted programmes 
addressing HIV among MSM positively impact on overall HIV 
rates in countries with generalised epidemics.6 The Soweto Men’s 
Study showed that 50% of African MSM participants also had sex 
with women, and high rates of HIV among MSM could be driving 
HIV incidence in South African women.7 All South Africans might 
therefore benefit from an immediate move to initiate MSM on ART 
at a CD4 count of 350 cells/ µl.
Background
HIV transmission is dependent on the route of acquisition, the 
infecting viral load and the presence of inflammation and activated 
immune system cells below mucosal surfaces.8 Addressing these 
factors lowers HIV transmissibility. Unprotected, especially receptive, 
anal sex remains a high-risk behaviour for HIV transmission with a 
transmission risk about 18 times higher than for penile-vaginal sex, 
and is a major driver of high HIV rates among MSM.9
IDUs who inject themselves with HIV-contaminated needles 
provide a direct access point for HIV, and established infection can 
therefore occur with relatively lower viral loads. CSWs are likely 
to transmit HIV if they become infected themselves because of 
the greater number of sex partners that they encounter. All these 
population groups benefit from targeted HIV programmes.
Addressing HIV among MSM
The odds ratio for African MSM testing HIV positive is 3.8 compared 
with their heterosexual male counterparts.10 Data confirm that African 
MSM are a particularly vulnerable group, and a high HIV prevalence 
has been recorded in South Africa with rates ranging between 10.4% 
and 33.9%.7,11 Reasons include the psychological impact of living in 
a heteronormative, stigmatising society, perceived barriers to health 
care, and sexual behaviours that facilitate transmission of HIV.
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Men who have sex with men (MSM) are at high risk for HIV 
acquisition and transmission owing to the high risks associated 
with unprotected anal sex and barriers to accessing appropriate 
health services.  Globally HIV prevention is failing among 
MSM, as evidenced by high seroconversion rates. Prevention 
interventions for MSM are more limited than for heterosexual 
individuals. Prevention programmes should embrace early 
initiation of antiretroviral therapy for positive clients as part of 
their programming. High transmission risk groups such as MSM 
will benefit from such interventions.
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Prevention of HIV transmission among MSM is failing worldwide 
with ongoing high seroconversion rates.12,13 MSM suffer from stigma 
and discrimination, which is often systematised and sanctioned 
by country leaders. The overwhelming prevalence of HIV 
among heterosexual individuals has resulted in messaging that is 
heteronormative and has failed to address the risks associated with 
unprotected anal sex.
HIV risk reduction tools for MSM are limited or are ineffective.12 
Condoms are effective, but use remains inconsistent. Latex-
compatible lubricants are required for anal sex with a condom, but are 
expensive and not widely available in Africa. Treatment of sexually 
transmitted infections (STIs) which cause mucosal disruption lowers 
HIV acquisition risk; however, STI incidence is increasing among 
MSM even in developed countries with good messaging and excellent 
health care infrastructures.14,15
Post-exposure prophylaxis (PEP) ART for MSM who may have 
been exposed to HIV is likely to be protective, although many 
structural barriers to access still exist. Proof of concept of the efficacy 
of pre-exposure prophylaxis (PrEP) comes from the iPrEx study 
in which long-term use of tenofovir and emtricitabine (Truvada) 
was associated with a 40% lower risk of seroconversion among 
MSM.16 Many issues relating to the implementation of PrEP remain, 
including concerns of increasing risky behaviours. PrEP remains 
unavailable to most African MSM.
Vaginal use of tenofovir-based gel can reduce a woman’s chance 
of becoming HIV infected by 39%;17 similar results have not been 
established for rectal microbicides, and more development work is 
needed to make this intervention applicable for MSM.
Male circumcision (MC) has become an important prevention tool 
for heterosexual men,18 but cannot protect men who acquire HIV 
infection anally. MC may provide some protection for MSM who 
practise exclusively penetrative anal sex.19-21 High levels of bisexual 
concurrency have been noted among some African MSM, who might 
benefit from MC to reduce their risk of vaginal acquisition of HIV.19 
There are no current recommendations to offer MC to MSM as a risk 
reduction strategy.
Preliminary reports from the HPTN 052 study showed that early 
ART initiation among HIV-discordant couples was associated with a 
96% reduction in HIV seroconversion.22 Although the participants 
in this study were predominantly heterosexual couples, it is plausible 
that this benefit will hold true for MSM. Considering the poor 
efficacy or availability of HIV risk-reduction interventions for MSM, 
early treatment with ART to lower viral load and thus infectivity of 
MSM is an immediately available and implementable intervention.4  
 State-supported MSM-targeted health services already exist in 
South Africa, namely the Ivan Toms (Cape Town) and Simon Nkoli 
(Soweto) Centres for Men’s Health, which are able to attract African 
MSM into sexual health and HIV care. These clinics previously missed 
the opportunity to initiate their clients on early treatment to improve 
individual outcomes and, importantly, begin to address high HIV 
transmission rates among these men.  The revised SAG guidelines will 
allow these concerns to be addressed.
Conclusion
The positive benefits of early ART initiation for HIV-positive MSM 
are clear. This strategy conforms to evidence-based ART initiation 
guidelines, which ideally should be implemented for the population 
at large when funding and resources allow, but urgently for MSM and 
other high-risk communities.
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